Article ID Journal Published Year Pages File Type
9323648 Fertility and Sterility 2005 4 Pages PDF
Abstract
In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 months) in the treatment of women with histologically proven rectovaginal endometriosis. In a series of 10 patients, dysmenorrhea, physical and social functioning, but not chronic pelvic pain and dyspareunia, improved during therapy.
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study
Authors
, , , ,